Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 330 (LINC00330)
- Target
- LINC00330
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Long intergenic non-protein coding RNA 330 (LINC00330) is a human long non-coding RNA (lncRNA) gene implicated in the regulation of tumor biology, especially via modulation of immune cell behavior and tumor microenvironment. LINC00330 has been shown to inhibit tumor progression in esophageal squamous cell carcinoma by promoting the polarization of tumor-associated macrophages (TAMs) from a tumor-promoting (M2) to a tumor-suppressing (M1) phenotype and by suppressing CCL2 signaling. Its reduced expression is associated with tumor aggressiveness and poor clinical outcomes in several cancers. LINC00330 also promotes the expression of epithelial markers while inhibiting mesenchymal markers, thereby limiting epithelial–mesenchymal transition and metastasis. LINC00330 is not currently known to be directly druggable nor does it interact with known small-molecule drugs, but its expression patterns support its use as a biomarker for cancer prognosis and potentially as a therapeutic target in future RNA-based therapies[1][2][3][5][7].
- Other names
- NCRNA00330LINC00330
02
Biological functions
Regulation of tumor-associated macrophage (TAM) polarizationModulation of epithelial–mesenchymal transition (EMT)Inhibition of cell proliferation and invasion in certain cancersRegulation of CCL2 signaling
03
Disease associations
Cancer (notably esophageal squamous cell carcinoma, bladder cancer, laryngeal cancer)Immune microenvironment modulation in cancer
04
Biomarkers
Prognostic marker in bladder cancerBiomarker for poor prognosis in esophageal squamous cell carcinoma (ESCC)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 330 (LINC00330).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 330 (LINC00330).